View Post

Phase I clinical trial of PAC-1 in patients with end-stage cancers shows promising results

In In The News by Barbara Jacoby

Source: University of Illinois at Urbana-Champaign From: A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers. The drug stalled the growth of tumors in the five people in the trial with neuroendocrine cancers and reduced tumor size in two of those …

View Post

First Trial of Immunotherapy in Early-Stage Triple-Negative Breast Cancer Shows Promising Results

In Clinical Studies News by Barbara Jacoby

By: Danielle Ternyila From: In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the findings from the interim analysis for the phase III KEYNOTE-522 study, which added pembrolizumab to neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer. The randomized, phase III KEYNOTE-522 clinical trial evaluated the benefit of adding the immune checkpoint inhibitor pembrolizumab (Keytruda) to …